New studies on Ozempic secure the Danish pharmaceutical company tailwind. This is how Novo Nordisk’s papers move on Friday.
• Strong study data: Ozempic convinces in the REACH study in cardiovascular diseases
• Growth driver Wegovy: Oral wording could open up additional market shares
• Analysts confident for Novo Nordisk share
Novo Nordisk share in focus
After a clear course of the course in Denmark, the Novo Nordisk share ultimately noted 0.99 percent lower at 388.60 crowns.
The positive development was driven the day before by publishing new data on the effectiveness of the Diabetes drug Ozempic. In the REACH study, the preparation not only showed a strong blood sugar control, but also significantly reduced the risk of heavy cardiovascular events.
Wegovy remains the central growth engine
In addition to Ozempic, Novo Nordisk is increasingly relating to his means of pathovy, which is used to treat obesity. The developments around an oral dosage form in particular ensure high expectations of sales potential. Market observers assume that Novo Nordisk will take a key role in a billion -dollar segment with this product in one billion -dollar segment.
Analysts see further potential
Despite an intensive competition with US competitor Eli Lilly, analysts are optimistic. While some leave their assessments unchanged, other banks adhere to clear purchase recommendations and ambitious course goals. For investors, this means that the stability of the stock could form the soil for the next upward movement.
Editor finance.net
By the way: Eli Lilly and other US shares are even tradable at Finance.net Zero until 11 p.m. (without order fees, plus spreads). Open Depot now for free And secure new customer bonus!
Selected leverage products on Eli Lilly
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Eli Lilly
The lever must be between 2 and 20
Advertising